Jefferies keeps Amgen at hold

Amgen, Inc. was maintained by Jefferies & Co., Inc. analyst Adam Walsh at hold with a $73 price target after the company reported solid pipeline data at the American Society for Clinical Oncology. The analyst looked for more data on Denosumab, Panitumumab, AMG-706 and Aranesp. Shares of the Thousand Oaks, Calif.-based biotechnology company were down $1.70, or 2.46%, at $67.48 on volume of 8,693,918 shares versus the three-month running average of 8,981,930 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.